Innovation and Patent Details
Restasis® is a topical treatment to remedy chronic dry eye disorder (keratoconjunctivitis - KCS) in humans.
Optimmune® is a topical treatment to remedy chronic dry eye disorder (keratoconjunctivitis - KCS) in canines.
Invention/Innovation Name
Restasis®
Optimmune®
Institution Where Invention/Innovation Developed
University of Georgia
Name(s) of Inventor(s)/Innovator(s) - Title - Advanced Degrees Held
Dr. Renee Kaswan, DVM, MS - Diplomate, American College of Veterinary Ophthalmologists
Revenue Generated (if applicable)
Restasis®: Allergan began selling Restasis® in April, 2003. The following revenue numbers are annual, with all years containing four quarters of revenue except 2003, which contains three.0
| 2003 |
$38,400,000 |
generated in Q2-Q4 |
| 2004 |
$99,800,000 |
24% quarter over quarter increase from 2003-2004 |
| 2005 |
$190,800,000 |
91.18% growth from 2004 to 2005 |
| 2006 |
$270,200,000 |
41.61% growth from 2005 to 2006 |
| 2007 |
$344,500,000 |
27.50% growth from 2006 to 2007 |
| 2008 |
$220,200,000 |
estimate provided by Allergan |
Revenues for sales of Restasis® in the five years since it has been on the market have exceeded $1.5 billion. Annual sales have increased between $61-$91 million each year. This is a staggering growth rate. Restasis® was the first, and continues to be the only, treatment for chronic dry eye which helps to increase the eye's natural ability to produce tears.
|
